# HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct06389500/  
OnCo record `nct06389500` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Harbin Medical University, not yet recruiting.

## Summary

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06389500 by Harbin Medical University, with a registry enrolment figure of 30 participants, started 2024-05-01 and due to reach its primary completion in 2027-05-01. Interventions recorded: Adebrelimab, Lenvatinib, Hepatic Arterial Infusion Chemotherapy. Conditions listed: Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "3. Borderline resectable, locally advanced biliary malignant tumors, including gallbladder cancer, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and distal cholangiocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06389500
- Phase: 2
- Setting: Hepatic Arterial Infusion Chemotherapy Combined With Adebrelimab and Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: a Single-arm, Exploratory Clinical Study
- Sponsor: Harbin Medical University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06389500: https://clinicaltrials.gov/study/NCT06389500

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06389500.json